ImmunityBio, Inc. — Director's Dealing 2026

Jan 21, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2026-01-20

Reporting Person: Simon Barry J. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-20	Common Stock	S	76967	$6.54	Disposed	3166604	Direct
2026-01-20	Common Stock	S	75000	$7.8791	Disposed	3091604	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F2: Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $7.87 to $7.8950 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.